Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Pascal Benkert
Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP
Abstract Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are biomarkers of neuroaxonal and astrocytic damage but remain understudied in adolescent psychiatric populations. This study investigated sNfL and GFAP levels in 412 adolescents diagnosed with anorexia nervosa (AN) (n = 52), depression (n = 237), and other psychiatric disorders (n = 123). We assessed their diagnostic utility, correlation with disease severity, and longitudinal changes during AN treatment.
Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis
|
Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis Key Points Question Are serum glial fibrillary acidic protein (GFAP) levels and their treatment-related changes associated with future progression independent of relapse activity (PIRA) in multiple sclerosis (MS)?
By Sofia Sandgren, Sabine Schaedelin, Kiarra Ning, Aleksandra Maceski, Johanna Oechtering, Christian Cordano, Lester Melie-Garcia, Jeffrey M. Gelfand, Alessandro Cagol, Roland Henry, Sebastian Finkener, Patrice H. Lalive, Stefanie Muller, Caroline Pot, Amandine Mathias, Renaud Du Pasquier, Robert Hoepner, Andrew Chan, Giulio Disanto, Chiara Zecca, Marcus D’Souza, Lars G Hemkens, Özgür Yaldizli, Bettina Fischer-Barnicol, Tobias Derfuss, Patrick Roth, Marina Herwerth, Claudio Gobbi, David Brassat, Björn Tackenberg, Rosetta Pedotti, Heinz Wiendl, Klaus Berger, Marco Hermesdorf, Georgina Arrambide, Fredrik Piehl, Henrik Zetterberg, Bruce A.C. Cree, Maria Pia Sormani, Ludwig Kappos, Stephen L. Hauser, Michael Khalil, Cristina Granziera, Ari J Green, David Leppert, Pascal Benkert, Ahmed Abdelhak, Jens Kuhle, Lisa M. Hofer, Michelle Hughes, Nafiye Genc, Riccardo Galbusera, Edoardo Galli, Jannis Müller, Veronika Kana, Catarina Raposo, Jorge R. Oksenberg, David Conen, Maximilian Einsiedler, Amar Zadic, Marjolaine Uginet
|
JAMA Network
Verified
Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis
|
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary Anti-CD20 therapies deplete B cells and are an effective disease-modifying treatment avenue for multiple sclerosis (MS). However, which B cell subtypes are responsible for this therapeutic success remains unknown. Here, Neziraj et al.
By Emily Hendrix, Heather Lin Verified, Aditya Barve, Tradite Neziraj, Elisabeth Pössnecker, Angela A. Wang, Paul Saary, Adrian-Minh Schumacher, Florian Ingelfinger, Amandine Mathias, Edoardo Galli, Michelle Zuo, Samuel Jones, Vasiliki Pantazou, Joep Killestein, Sabine Schädelin, Pascal Benkert, Cristina Granziera, Caroline Pot, Antje Bischof, Jan Hendrik Niess, Tobias Derfuss, Charlotte Teunissen, Marco Häfelfinger, Magdalena Filipowicz Sinnreich
|
Science Magazine
Verified
Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Hereditary Transthyretin Amyloidosis Polyneuropathy
ATTRv hereditary transthyretin amyloidosis BMI body mass index CADT Compound Autonomic Dysfunction Test CMAP compound muscle action potential ESC electrochemical skin conductance FAP familial amyloid polyneuropathy GFAP glial fibrillary acidic protein HC healthy controls NCS nerve conduction studies NfL neurofilament light chain NIS Neuropathy Impairment Score NIS-LL NIS lower limb NIS-UL NIS upper limb PND Polyneuropathy Disability Score QOL-DN Norfolk Quality of Life in Diabetic Neuropathy...
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis
1 Introduction Triggering receptor expressed on myeloid cells 2 (TREM2) is a surface receptor expressed on microglia that facilitates the clearance of myelin debris and the removal of apoptotic cells, thereby supporting tissue repair and regeneration [1]. Blocking TREM2 aggravated experimental autoimmune encephalomyelitis [2], whereas TREM2 overexpression enhanced recovery [3].
Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis
1 Introduction Multiple sclerosis (MS) is a chronic condition characterized by demyelination, inflammation, and neurodegeneration within the central nervous system (CNS). Magnetic resonance imaging (MRI) plays a pivotal role in the diagnosis and clinical management of people with MS (pwMS), primarily by enabling the detection of white matter lesions (WMLs).
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study
BACKGROUND: Serum neurofilament light (sNfL) chain levels, a sensitive measure of disease activity in multiple sclerosis (MS), are increasingly considered for individual therapy optimization yet without consensus on their use for clinical application. OBJECTIVE: We here propose treatment decision algorithms incorporating sNfL levels to adapt disease-modifying therapies (DMTs).
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis
Multiple sclerosis (MS) is a disabling disease of the central nervous system with 2 main pathophysiological hallmarks: neuroinflammation and neurodegeneration.
Neurofilaments as biomarkers in neurological disorders — towards clinical application - Nature Reviews Neurology
Abstract Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and simplify longitudinal follow-up has paved the way for the development of neurofilaments as a biomarker in clinical practice.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
NF and PB are joint first authors. X @J_SastreGarriga, @Enric_Monreal XM and MC contributed equally. Contributors NF, XM and MC: Design and conceptualised study; acquisition of the data; drafted the manuscript for intellectual content. PB: Design and conceptualised study; analysed the data; drafted the manuscript for intellectual content.
MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial
Abstract Background: Treatment decisions for persons with relapsing-remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians.
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study - Xavier Mo
Abstract Evobrutinib – an oral, central nervous system (CNS)-penetrant, and highly selective Bruton’s tyrosine kinase inhibitor – has shown efficacy in a 48-week, double-blind, Phase II trial in patients with relapsing MS. Report results of the Phase II open-label extension (OLE; up to week 192 from randomisation) and a cerebrospinal fluid (CSF) sub-study.
Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performance
1 INTRODUCTION Obstructive sleep apnea (OSA) is the most common primary sleep disorder in adults, with about a billion estimated cases worldwide (Benjafield et al., 2019). Although the prevalence has significantly increased in our aging and more obese society, OSA remains largely undiagnosed and untreated (Watson, 2016).
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
NF and PB are joint first authors. Twitter @J_SastreGarriga, @Enric_Monreal XM and MC contributed equally. Contributors NF, XM and MC: Design and conceptualised study; acquisition of the data; drafted the manuscript for intellectual content. PB: Design and conceptualised study; analysed the data; drafted the manuscript for intellectual content.
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis Audio (19:03) 0:00 / 0:00 Key Points Question When does neuroaxonal pathology occur in people with multiple sclerosis (MS) who experience disability worsening?
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study
Summary Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority.
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
Summary Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level.
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis
1. Giovannoni, G, Turner, B, Gnanapavan, S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 2015; 4(4): 329–333. Google Scholar | Crossref | Medline 2. Havrdova, E, Galetta, S, Stefoski, D, et al. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(Suppl. 3): S3–S7. Google Scholar | Crossref | Medline 3. Hegen, H, Bsteh, G, Berger, T. ‘No evidence of disease activity’—is it an appropriate surrogate in multiple sclerosis?
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS - Jens Kuhle, Nadia Daizadeh, Pascal Benkert, Aleksandra Maceski, Christian Barro, Zuzanna Michalak, Maria Pia Sormani, Jean Godin, Srinivas
1. Gafson, AR, Barthelemy, NR, Bomont, P, et al. Neurofilaments: Neurobiological foundations for biomarker applications. Brain 2020; 143(7): 1975–1998. Google Scholar | Crossref | Medline 2. Barro, C, Benkert, P, Disanto, G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018; 141(8): 2382–2391. Google Scholar | Crossref | Medline 3. Chitnis, T, Gonzalez, C, Healy, BC, et al.
Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis
Research Article Johanna Oechtering MD, Neurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) University Hospital Basel, University of Basel, Switzerland Search for more papers by this author Sabine Schaedelin MSc, Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland Search for more papers by this author Pascal Benkert PhD, Clinical Trial Unit, Department of...
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate
Cite article Cite article If you have citation software installed, you can download article citation data to the citation manager of your choice Select your citation manager software: Information, rights and permissions Information Published In Article first published online: May 28, 2020 Issue published: March 2021 Keywords Multiple sclerosis disability progression disease-modifying therapies relapsing/remitting Rights and permissions © The Author(s), 2020. Request permissions for this article.
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Abstract Objective To determine factors (including the role of specific disease modulatory treatments [DMTs]) associated with (1) baseline, (2) on-treatment, and (3) change (from treatment start to on-treatment assessment) in plasma neurofilament light chain (pNfL) concentrations in relapsing-remitting multiple sclerosis (RRMS).
The influence of age at disease onset on future relapses and disability progression in multiple sclerosis patients on immunomodulatory treatment
ORIGINAL ARTICLE Özgür Yaldizli Corresponding Author E-mail address: oezguer.yaldizli@usb.ch https://orcid.org/0000-0002-0800-4845 Neurologic Clinic and Policlinic, Departments of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland Corresponding Author: Dr Özgür Yaldizli, University Hospital Basel, Department of Neurology, Petersgraben 4, 4031 Basel Email: oezguer.yaldizli@usb.ch Search for more papers by this author This article has been accepted for publication...
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Blood neurofilament light levels segregate treatment effects in multiple sclerosis Bénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, Pascal Benkert, Zuzanna Michalak, Ludwig Kappos, David Leppert, Jon A. Tsai, Tatiana Plavina, Bernd C. Kieseier, Jan Lycke, Lars Alfredsson, Ingrid Kockum, Jens Kuhle, Tomas Olsson, Fredrik Piehl Neurology Feb 2020, 10.1212/WNL.0000000000009097; DOI: 10.1212/WNL.0000000000009097
Serum neurofilament light levels in normal aging and their association with morphologic brain changes
Abstract Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured not only in cerebrospinal fluid but also in serum, which allows for repeated assessments. There is still limited knowledge regarding the association of serum NfL (sNfL) with age and subclinical morphologic brain changes and their dynamics in the normal population.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Pascal
Contact Pascal, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack